Navigation Links
NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd
Date:8/25/2009

NEW YORK, Aug. 25 /PRNewswire-FirstCall/ -- NeoStem Inc. (NYSE Amex: NBS) which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the Company's CEO, Robin Smith, M.D. MBA, has been invited to participate in the 2009 World Stem Cell Summit to be held in Baltimore, Maryland, next month.

Dr. Smith will participate on the panel, "Cord Blood and Cell Banking: Answers for Patients, Researchers and Industry," scheduled for Wednesday, September 23rd, from 4:00 to 5:15 PM. She will be one of 100 presenting experts, attendees from 36 countries and representatives from more than 151 sponsors and supporting organizations and media partners at this preeminent international networking event.

The 2009 Summit will take place September 21-23 at the Baltimore Convention Center. It is presented by the Genetics Policy Institute and hosted by Johns Hopkins University, the University System of Maryland, and the State of Maryland. The comprehensive, multi-track program covers advanced science, commercial perspectives, disease progress reports and in-depth reviews of policy, law, ethics, regulatory issues and global economic development.

Dr. Smith stated, "I am very pleased to take part in this international Summit, as it brings together leading researchers, scientists, industry leaders, funders, policy makers, advocates, educators and regulators who are charting the future of regenerative medicine. This field has gained enormous vitality in just the past couple of years. I am proud that NeoStem Inc. is on the forward edge of new therapies and technologies whose potential to save and change many lives is expanding exponentially."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China. For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

             CONTACT:
             NeoStem, Inc.
             Robin Smith, Chief Executive Officer
             T: 212-584-4180
             E: rsmith@neostem.com

'/>"/>
SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
2. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
3. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
4. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
5. NeoStem Featured in Business Week; Promising Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article
6. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
7. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
8. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
9. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
10. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
11. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):